Associated Papers
1q jumping translocation as a biomarker in myeloid malignancy: frequently mutated genes associated with bad prognosis and low survival.
Halper-Stromberg E et al.
Experimental Hematology & Oncology, 2024
39090734 (PubMed )
Supplement: 40164_2024_541_MOESM1_ESM.pdf
Cellular distribution of IDH mutations in AML during morphologic remission.
Ramanan R et al.
Leukemia Research, 2023
IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
Molenaar RJ et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society, 2022
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.
Ribeiro S et al.
Cancers, 2021
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.
Choe S et al.
Blood Advances, 2020
Select a paper to view details